Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Biogen Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $29.4B | |
|---|---|---|
| Revenue (ttm) | 10.3B | |
| Net income (ttm) | 347.5M | |
| EPS (ttm) | $2.33 | |
| Shares out | 147.8M | |
| P/E (trailing) | 104.5x | |
| P/E (forward) | 12.0x | |
| Volume | 1,868,119 | |
| Beta | 0.09 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $10.17B | $9.84B | $9.68B | $9.89B | -0.9% |
| Gross profit | $7.90B | $7.30B | $7.37B | $7.49B | -1.8% |
| Operating income | $3.84B | $1.54B | $2.16B | $1.82B | -22.0% |
| Net income | $3.05B | $1.16B | $1.63B | $1.29B | -24.9% |
| EPS (diluted) | $20.87 | $7.97 | $11.18 | $8.79 | -25.0% |
| EBITDA | $4.36B | $2.04B | $2.83B | $2.60B | -15.8% |
| R&D | $2.23B | $2.45B | $1.98B | $1.78B | -7.3% |
| SG&A | $2.40B | $2.55B | $2.40B | $2.43B | +0.4% |
Recent company headlines from major financial publishers.
Leqembi dominates the Alzheimer's market with seamless logistical rollout, accelerating revenue and EPS growth back to high single digits.
Leqembi scales moderately, offsetting the decline of the legacy MS franchise, allowing baseline EPS growth.
| Ke ↓ / g → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 5.6% | $308 | $345 | $393 | $443 | $443 |
| 6.6% | $253 | $278 | $308 | $345 | $393 |
| 7.6% | $215 | $232 | $253 | $278 | $308 |
| 8.6% | $187 | $200 | $215 | $232 | $253 |
| 9.6% | $165 | $175 | $187 | $200 | $215 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
